Eli Lilly Resets Merger Review Clock On $2.4B Deal
By Matthew Perlman · July 25, 2023, 7:26 PM EDT
Pharmaceutical giant Eli Lilly & Co. has given enforcers more time to review its planned $2.4 billion deal for biopharmaceutical company Dice Therapeutics Inc. and also gave Dice's investors additional time...
To view the full article, register now.